Date of Report (Date of earliest event reported):
|
|
|
(Exact name of registrant as specified in its charter)
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code:
|
(
|
(Former name or former address, if changed since last report.)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
Item 2.02 |
Results of Operations and Financial Condition
|
Item 9.01 |
Exhibits.
|
(d) |
Exhibits
|
Exhibit No.
|
Description
|
ADMA Biologics, Inc. Press Release, dated August 10, 2022
|
|
104
|
Cover Page Interactive Data File (embedded with the Inline XBRL document)
|
* |
The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
August 10, 2022
|
ADMA Biologics, Inc.
|
||
By:
|
/s/ Brian Lenz
|
||
Name:
|
Brian Lenz
|
||
Title:
|
Executive Vice President and Chief Financial Officer
|